A comparison of the effect of alendronate and You-Gui-Wan on osteoporosis in female rats with kidney-yang deficiency

Background:In traditional Chinese medicine,You-Gui-Wan(YGW)is typically used to treat osteoporosis associated with kidney-yang deficiency.However,there have been few mechanistic studies on the effectiveness of kidney-yang deficiency-type osteoporosis with YGW.To further clarify the role of YGW in the effect of osteoporosis with kidney-yang deficiency,the study analyzed the therapeutic advantages of YGW by comparing the therapeutic effects of YGW and alendronate(ALN)on osteoporosis with kidney-yang deficiency.Methods:SPF female SD rats were randomly divided into control,osteoporosis,osteoporosis with kidney-yang deficiency,osteoporosis with kidney-yang deficiency+YGW and osteoporosis with kidney-yang deficiency+ALN groups.Except for the control group,osteoporosis was induced by the removal of bilateral ovaries.After 12 weeks,rats with osteoporosis in the kidney-yang deficiency group had kidney-yang deficiency syndrome triggered by hydrocortisone for 14 days.Rats were treated with YGW or ALN for 12 weeks.The weights of rats were recorded.Hematoxylin-eosin staining staining was used to observe pathological changes in bone trabeculae,liver,spleen,and kidneys of rats.Depletion of the growth plate cartilage of rats in different groups was observed by safranine-O staining.The expression of osteoclast key indices(ACP)and osteoblast key indices(ALP)in the bone tissue of rats in the different groups was observed by immunohistochemical staining.The expression of bone resorption-related indicators(TRAP and NXT-1),bone formation-related indicators(BALP,BGP,and P1NP),and major indicators of kidney-yang deficiency(ACTH,T3,T4,cAMP,and cGMP)were observed using an ELISA detection kit.The expression levels of the main indices of liver function(ALT and AST)were detected in different groups.Results:The differences between the osteoporosis with kidney-yang deficiency group and osteoporosis group were that the weight of rats and the expression of ACTH,T3,T4,and cAMP decreased significantly,and the expression of cGMP increased in the osteoporosis with kidney-yang deficiency group.Moreover,both YGW and ALN effectively improved the symptoms of osteoporosis,including the injury of bone trabeculae and growth plates,as well as the expression of bone metabolism-related indicators.However,unlike ALN,YGW simultaneously ameliorated the expression of key indicators of kidney-yang deficiency and prevented weight loss in rats.In addition,YGW caused no obvious damage to the liver,spleen,or kidney,whereas ALN led to liver cirrhosis.Conclusion:The results reveal that YGW plays a crucial part in osteoporosis with kidney-yang deficiency,increases bone mineral density,and improves bone metabolism indicators,and is safe and efficient for the efficacy of osteoporosis with kidney-yang deficiency.YGW might have a better therapeutic effect on osteoporosis in patients with kidney-yang deficiency.Therefore,alendronate should be used cautiously in patients with osteoporosis and poor liver function.

Observation of tongue picture and tongue and nailbed microcirculation before and after blood dialysis in 125 uremic patients with deficiency of kidney-yang

using a WZD—1 microcirculation microscope,we observed the tongue tipand nail-bed microcirculation of uremic patients with deficiency of kidney-yangbefore and after blood dialysis.The results showed that the pathological basis ofuremia with deficiency of kidney-yang may be microcirculation disturbance,in-crease of metabolites and water retention.The effusion from capillary loops intongue tip may be one of the pathogenetic factors of a swollen and jaggedtongue.The flow rate of blood in capillary loops in the nail-bed was apparentlyabnormal and markedly improved after blood dialysis.The weighted integral ofnail-bed microcirculation decreased from moderately abnormal (4.99±1.52) toapproximately normal (1.98±0.97) (P【0.01).Microcirculation seems to be a sensi-tive criterion for reflecting the pathologic changes of uremia with deficiency ofkidney-yang.

Clinical Research of Zhenwu Decoction Combined with Tingli Dazao Xiefei Decoction in the Treatment of Chronic Heart Failure with Edema Syndrome due to Yang Deficiency

[Objectives]The paper was to investigate the clinical effects of Zhenwu Decoction combined with Tingli Dazao Xiefei Decoction in the treatment of chronic heart failure with edema syndrome due to yang deficiency.[Methods]Eighty patients with chronic heart failure were randomly divided into 2 groups(control group and treatment group),with 40 cases in each group.The patients in the control group were treated with conventional western medicine for 14 d,and the patients in the treatment group were treated with Zhenwu Decoction and Tingli Dazhao Xiefeng Decoction on the basis of the control group for 14 d.The curative effect of traditional Chinese medicine(TCM)syndrome score,left ventricular ejection fraction(LVEF),plasma N-terminal brain natruretic peptide precursor(NT-proBNP)and New York Heart Association(NYHA)functional class were compared between the two groups before and after treatment.Minnesota living with heart failure questionnaire in the principle of Chinese civilization and traditional medicine characteristics(C-MLHF)at admission and 1 month after discharge were compared between the two groups.[Results]After treatment,the total effective rate of TCM syndrome score in the treatment group was 82.50%,and that in the control group was 67.50%.The curative effect of TCM syndrome score in the treatment group was better than that in the control group(P<0.05).After treatment the LVEF in both groups was increased compared with that before treatment,and the NT-proBNP level was decreased compared with that before treatment(P<0.05),and those in the treatment group were better than those in the control group.The total effective rate of cardiac function in the treatment group was 87.50%,and that in the control group was 65.00%.The improvement of cardiac function in the treatment group was better than that in the control group(P<0.05).One month after discharge,C-MLHF scores in both groups were decreased compared with those before treatment,and that in the treatment group was lower than in the control group(P<0.05).[Conclusions]Zhenwu Decoction combined with Tingli Dazao Xiefei Decoction based on traditional western medicine treatment could improve the clinical efficacy,symptoms and quality of life of patients in the treatment of chronic heart failure with edema syndrome due to yang deficiency.

阴虚水肿浅见

水肿病与肺的通调、脾的转输、肾的水液代谢调节、肝的疏泄、心的行血、三焦的气化有关。多数医家认为水为阴邪,得温则化,故虚证水肿多与脾肾阳气虚损有关,治疗常应用具有温热作用的中药以化水。但阴虚水肿亦不少见。阳虚、阴虚均可导致水肿的发生,现代医家多重视阳虚水肿,对阴虚水肿有所忽视。故此文对阴虚水肿的病因及治疗方剂(济阴汤、白茅根汤、加减八味地黄汤、滋阴清燥汤、猪苓汤)进行论述,尤推《医学衷中参西录》之济阴汤、白茅根汤、加减八味地黄汤。

高艳霞教授从气虚论治特发性膜性肾病经验

高艳霞教授认为特发性膜性肾病(Idiopathic membranous nephropathy,IMN)的总体病机以脾肾气虚为本,湿热瘀阻为标,虚实兼杂,虚实相因。临证多采用“补、清、通”三法并施,治以益气健脾补肾、活血清热除湿。自拟芪术固肾方,重用补气之品,随症灵活化裁,临床疗效显著。附典型病案一则。

从肝脾论治视网膜静脉阻塞继发黄斑水肿

根据肝脾与目的关系,从肝脾两脏生理上相互为用、病理上相互传变的特点出发,分析肝郁脾虚在视网膜静脉阻塞继发黄斑水肿(Macular edema secondary to retinal vein occlusion,RVO-ME)发生发展中的作用,结合疾病临床特点,认为RVO-ME的病机本质为肝郁脾虚,以致痰湿等病理产物堆积,形成肝郁脾虚-痰湿瘀血-肝郁脾虚的恶性循环,致使机体正虚邪实形成黄斑水肿。因此文中从肝脾理论出发,以疏肝健脾为主要治疗原则,以期丰富RVO-ME的中医病机理论和临床辨证施治证据。

浅议肺饮病之论治

肺饮病病位在肺,涉及脾、肾、心等脏,病性为本虚标实之证,病机以肺阳亏虚为本,气、血、水紊乱为标,西医中的肺水肿即属于肺饮病范畴。肺水肿是指肺内组织液的生成和回流平衡失调,大量肺毛细血管内的组织液经过外渗,积聚在肺泡、肺间质和细支气管内,使肺血管外液量增多,从而造成肺的通气与换气功能严重障碍的病理状态。中医在治疗上需要分清标本虚实,注重肺与其他脏腑联系,急性期以温阳利水、化痰理气为主,缓解期以温肺助阳、健脾益肾为主,突出“以温药和之”的治疗原则,用药应标本兼顾、补虚泄实,使得复杂病症得以合理有效的治疗。

白芍治疗阴虚水肿探析

白芍为补虚药,养血补虚之作用应用广泛,然对于白芍治疗水肿的研究甚少。为探明白芍疗水肿之功效,通过考查白芍利水源流,结合张锡纯及历代其他医家运用白芍治疗水肿的经验,阐明阴虚与水肿的内在联系,提出白芍功效以滋阴为主、利水为辅,通过滋补脾阴、养血柔肝、凉降泄热3个方面治疗水肿,为阴虚水肿的首选药物,并总结白芍配伍茯苓、阿胶、熟地黄、山药等药物作为常用药对,扩展了白芍的临床应用范围。

基于“阳虚阴结”理论探析温阳法论治特发性膜性肾病

膜性肾病是成人肾病综合征常见的病理类型之一,其中病因未明者称为特发性膜性肾病,中医学将其归属于“水肿病”范畴。“阳虚阴结”理论源于《素问·阴阳应象大论篇》中“阳化气,阴成形”。阳化气不足,阴成形太过,造成痰饮、水湿、瘀血等有形之物聚积,从而产生“阳虚阴结”的病理状态,发为特发性膜性肾病。张琳教授基于此提出,用温阳法论治特发性膜性肾病思路的方法和实践经验,强调温肾阳以化气利水湿。张琳教授临证时将温阳法视为特发性膜性肾病的治疗总纲,即“益火之源,以消阴翳”,注重调补脾肾、温阳散寒通络;同时针对有形实邪,予以温阳化湿、温阳化瘀,并附验案一则以供临床参考。

温阳利水方治疗慢性心力衰竭阳虚水泛证的临床研究

目的探讨温阳利水方治疗阳虚水泛证慢性心力衰竭的临床疗效。方法纳入2020年11月-2021年11月收治的心功能分级为Ⅱ~Ⅲ级的慢性心力衰竭患者82例,采用随机数字表法,分为治疗组和对照组各41例。2组均予常规西药治疗,治疗组加服温阳利水方,2组均治疗14d后评价其临床疗效,比较2组治疗前后中医证候疗效、血清N末端前脑钠肽(NT-proBNP)、生活质量评分、6 min步行距离。结果治疗后,2组血清NT-proBNP明显下降,治疗组较对照组下降更为显著(P<0.05);2组患者的活动耐力、生活质量均明显改善,治疗组改善较对照组更为显著(P<0.05);治疗组总有效率90.24%,显著高于对照组78.05%(P<0.05)。结论在常规西药治疗基础上加用温阳利水方能改善患者的临床症状和降低NT-proBNP、提高生活质量和活动耐力。

和血明目片联合阿柏西普治疗糖尿病性黄斑水肿疗效观察

[目的]观察和血明目片联合阿柏西普治疗糖尿病性黄斑水肿阴虚夹瘀证的临床疗效。[方法]选取糖尿病性黄斑水肿阴虚夹瘀证患者63例作为研究对象,随机分为观察组32例和对照组31例。两组均予阿柏西普玻璃体腔内注射,每眼每次0.05 ml,每月1次,连续治疗5个月。在此基础上,观察组同时予和血明目片常规剂量口服。比较两组临床疗效,治疗前后的中医症状及体征评分、最佳矫正视力、黄斑中心凹视网膜厚度、血清炎症因子水平、D-二聚体水平,随访1年内阿柏西普的注药次数。[结果]两组患者共脱落12例,最终观察组27例和对照组24例完成观察。观察组临床疗效优于对照组,差异有统计学意义(P<0.05)。治疗后两组视物模糊、眼前黑影、微血管瘤、眼底出血及眼底渗出均明显改善(P<0.05);观察组口渴多饮、心烦失眠、头晕目眩均明显改善(P<0.05),但对照组无明显改善(P>0.05);治疗后各项症状和体征评分观察组均优于对照组(P<0.05)。治疗后两组最佳矫正视力提高,黄斑中心凹视网膜厚度减小,且观察组显著优于对照组(P<0.05)。两组血清炎症因子、D-二聚体水平均较治疗前降低,且观察组显著低于对照组(P<0.05)。两组随访1年,观察组阿柏西普注药次数少于对照组,差异有统计学意义(P<0.05)。[结论]和血明目片联合阿柏西普治疗糖尿病性黄斑水肿阴虚夹瘀证患者,不仅能改善临床症状及体征,提高视力,促进黄斑水肿消退,改善血液高凝状态及抑制血清炎症因子,还可减少阿柏西普注药次数。

温氏奔豚汤加味联合火龙灸对脾肾阳虚型肾性水肿的疗效分析

目的:探讨温氏奔豚汤加味联合火龙灸对脾肾阳虚型肾性水肿的疗效分析。方法:本次前瞻性研究的受试对象为2022年1月—2023年6月就诊于梧州市中医医院的80例肾性水肿患者,研究开始前按照就诊顺序选取信封分为治疗组和对照组,每组40例。对照组采取常规肾性水肿对症治疗方案,治疗组在此基础上行温氏奔豚汤加味联合火龙灸治疗。两组治疗周期为4周。比较两组患者中医证候评分变化及临床疗效;比较两组患者治疗前后双踝部周径、双侧大腿围周径、血浆白蛋白、血肌酐、24 h尿蛋白定量水平;比较两组患者治疗前后肌酐清除率(CCr)、β2-微球蛋白(β2-MG)含量;观察两组患者治疗期间安全性事件。结果:治疗后治疗组中医证候评分、双踝部周径、双侧大腿围周径、血肌酐、24 h尿蛋白定量、β2-MG均低于对照组(P<0.05,P<0.01)。治疗组总有效率95.00%(38/40)显著高于对照组80.00%(32/40)(P<0.05);治疗组血浆白蛋白、CCr明显高于对照组(P<0.05,P<0.01)。两组均未出现严重安全性事件。结论:温氏奔豚汤加味联合火龙灸对脾肾阳虚型肾性水肿患者疗效较好,可显著减轻患者水肿程度,改善微循环障碍,其机制可能与减轻肾小球和肾小管间质病变有关。

基于虚瘀湿郁理论探讨中医治疗乳腺癌相关性淋巴水肿

此文介绍基于“虚、瘀、湿、郁”理论中医治疗乳腺癌相关性淋巴水肿的经验。正气不足,手术外伤,肝郁脾虚,湿瘀互结是乳腺癌相关性水肿发病的基础,此病病位在患侧上肢,局部辨证认为气虚血瘀,湿热内蕴,水湿停聚是此病发生的关键;整体辨证重在强调患者脏腑功能失调,分析得出肺、脾(胃)、肝三脏气机调节失常是局部气血失调的根本原因,即局部辨证包含于整体辨证之中。在针刺治疗方面,运用揿针,在患者健侧及远端取十二经脉的脾、肝、肺、心之原穴,任脉的关元、中脘,标本兼治,达到疏通经络气血、调节脏腑阴阳的目的。

从阴虚湿热论治难治性RVO-ME

视网膜静脉阻塞(RVO)是一种常见的高致盲性视网膜血管疾病,其影响患者视力的主要并发症为视网膜静脉阻塞继发黄斑水肿(RVO-ME)。中医学认为血瘀为RVO-ME致病关键因素,但仅从“化瘀”治疗效果却不尽如人意。本文通过阐释阴虚、湿热与ME的关系,将辨证与辨病相结合,从病因病机方面论述阴虚湿热为RVO-ME缠绵不愈的核心病机。以此为指导,提出养阴清热利湿的治疗法则,同时配合理气化瘀之法,并根据患者病情不同提出相应方药。养阴清热利湿的治法寓含盛者责之、虚者责之理论,养阴而不助邪,清热利湿而不伤阴,力求为RVO-ME缠绵不愈的治疗开拓出新的理论思路及临床方案。

Efficacy of suspended moxibustion stimulating Shenshu(BL23)and Guanyuan(CV4)on the amygdala-HPA axis in rats with kidney-Yang deficiency symptom pattern induced by hydrocortisone

OBJECTIVE:To investigated the effects of suspended moxibustion stimulating Shenshu(BL23)and Guanyuan(CV4)acupoints on the amygdala and HPA axis in our rat model and elucidated the possible molecular mechanisms of moxibustion on kidney-Yang deficiency symptom pattern(KYDS).METHODS:Sixty male Sprague Dawley rats were randomly divided into a control group(n=12)and an experimental group(n=48).Rats in the experimental group were given intramuscular injections of hydrocortisone to establish a KYDS model.The 48 rats successfully modeled were then randomly divided into a model group(model,n=12),a carbenoxolone intraperitoneal injection group(CBX,n=12),a moxibustion group(moxi,n=12),and a moxi+CBX group(n=12).In the moxi,the Shenshu(BL23)and Guanyuan(CV 4)acupoints were treated with moxibustion for 14 d.After treatment,measures were taken of serum levels of corticosterone(CORT),adrenocorticotropic hormone(ACTH),and corticotropinreleasing hormone(CRH).The expression of mineralocorticoid receptors(MRs),glucocorticoid receptors(GRs),11beta-hydroxysteroid dehydrogenase type 1(11β-HSD1),CRH,and ACTH in the rats’amygdala,hypothalamus,or pituitary(as appropriate)was detected.Data were analyzed using one-way analysis of variance.RESULTS:Compared with those of the control group,the serum levels of CRH,ACTH,and CORT;the mRNA and protein expressions of MR,GR,and 11β-HSD1 in the amygdala;the mRNA and protein expressions of 11β-HSD1 in the hypothalamus;the CRH mRNA expression in the amygdala and hypothalamus;and the ACTH mRNA expression in the pituitary of the rats in the model group were all significantly decreased(P<0.05 or 0.01).After treatment with moxibustion,all the aforementioned observation indices except for 11β-HSD1 m RNA expression were ameliorated compared with those in the model group(P<0.05 or 0.01).CONCLUSIONS:Suspended moxibustion can effectively improve the serum levels of ACTH,CRH,and CORT and can up-regulate the mRNA and protein expressions of MR,GR,11β-HSD1,CRH,and ACTH in the amygdala and hypothalamus of KYDS rats.This may be one of the molecular mechanisms with which moxibustion alleviates KYDS.

补肺温肾汤联合穴位埋针治疗阳虚水泛证肺胀临床研究

目的:观察补肺温肾汤联合穴位埋针治疗阳虚水泛证肺胀的临床效果。方法:选择96例阳虚水泛证肺胀患者作为研究对象,随机分为联合组和对照组各48例。对照组给予常规西医治疗,联合组在常规西医治疗基础上给予补肺温肾汤内服联合穴位埋针治疗。连续治疗2周后,比较2组临床疗效、中医证候评分、呼吸困难程度[改良版英国医学研究委员会呼吸困难量表(mMRC)评分]、生活质量[慢阻肺自我评估问卷(CAT)评分]、肺功能[用力肺活量(FVC)、第1秒用力呼气量(FEV_(1))、FEV_(1)/FVC]、心功能[左心室射血分数(LVEF)]和不良反应发生率。结果:治疗后,联合组总有效率为93.75%,对照组为79.17%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组中医证候评分、mMRC评分、CAT评分均较治疗前降低(P<0.05),且联合组中医证候、mMRC、CAT评分均低于对照组(P<0.05)。治疗后,2组FVC、FEV_(1)、FEV_(1)/FVC水平均较治疗前升高(P<0.05),且联合组3项肺功能指标均高于对照组(P<0.05)。治疗后,2组LVEF水平较治疗前升高(P<0.05),且联合组LVEF水平高于对照组(P<0.05)。联合组不良反应发生率为8.33%,对照组为6.25%,2组比较,差异无统计学意义(P>0.05)。结论:补肺温肾汤联合穴位埋针治疗阳虚水泛证肺胀可进一步减轻临床症状,改善心肺功能,提高生活质量,且安全性良好。

温阳利水活血方联合香山正骨手法复位小夹板固定治疗阳虚水泛型桡骨远端骨折肿胀临床研究

目的:观察温阳利水活血方联合香山正骨手法复位小夹板固定治疗阳虚水泛型桡骨远端骨折肿胀的临床疗效。方法:采用随机数字表法将70例阳虚水泛型桡骨远端骨折肿胀患者分为治疗组与对照组各35例。对照组采用香山正骨手法复位小夹板固定治疗,治疗组在对照组基础上加用温阳利水活血方治疗。比较2组治疗前后中医证候积分、肿胀度、腕关节活动度、桡骨高度水平,比较2组骨折愈合率、临床疗效及不良反应发生情况。结果:治疗后,2组总有效率、不良反应发生率比较,差异无统计学意义(P>0.05)。2组治疗后腕关节桡偏、尺偏、掌屈、背伸活动度及桡骨高度均较治疗前升高(P<0.05),中医证候积分降低(P<0.05);治疗组治疗后中医证候积分低于对照组(P<0.05),骨折愈合率、腕关节桡偏、尺偏、掌屈、背伸活动度及桡骨高度高于对照组(P<0.05)。2组治疗3 d、1周、2周、4周后肿胀度较治疗前降低(P<0.05),且治疗组治疗1周、2周、4周后肿胀度低于对照组(P<0.05)。结论:温阳利水活血方联合香山正骨手法复位小夹板固定治疗阳虚水泛型桡骨远端骨折肿胀疗效确切,能够有效消除肿胀,改善腕关节活动度,防止桡骨高度丢失,安全性较高。

梁群基于急性虚证诊疗脓毒症肾病的临床思辨经验

脓毒症伴急性肾损伤(AKI)在临床中存在着高发病率及致死率,目前尚无有效药物对此进行治疗,预后较差[1]。梁群教授深挖中医古籍,结合大量临床观察,在治疗脓毒症肾病方面形成了自己独有的见解。作者在跟师学习及对典型医案归纳、整理的过程中,初步总结了梁群教授基于急性虚证治疗脓毒症肾病的临证思想。梁群教授认为急性虚证是此病基本的病理基础和病机特点,而湿浊瘀毒继发是最典型的病机特点,水湿泛滥是病情进一步恶化的体现。在辨证的过程中,以急性虚证为基础,重点辨有无瘀血及水肿,治疗以益气扶正为主,强调截断治疗,提早大剂重用益气温阳兼活血利水取得诸多良效。

基于文献研究的肾性水肿思路探析

通过对中医药古籍代表著作的梳理,探究肾性水肿的病因病机、治法方药等思路方法。如《内经》提出肾性水肿与外邪、内虚有关,并且确立治则治法;《难经》初步确立三焦、命门与肾性水肿的关系;《伤寒论》重视外感病合并水肿的治疗;《金匮要略》定义肾水,重视脉象;《诸病源候论》广揽医籍,以脾肾俱虚立论,关注预后;《千金要方》收载药食针穴,重视食疗;《外台秘要》引经据典,总结水肿证因脉治;《针灸甲乙经》整理针刺处方,重视保护胃气等。经过系统梳理后发现,历代医著对肾性水肿辨治框架基本完善,兼顾食疗摄养,为后世医家辨治奠定了理论基础。

养心益肾温阳利水法结合常规西药治疗冠心病心力衰竭临床研究

目的:观察养心益肾温阳利水法结合常规西药治疗冠心病心力衰竭(心肾阳虚水泛证)的临床疗效。方法:选取冠心病心力衰竭(心肾阳虚水泛证)患者96例,按随机数字表法分为对照组和观察组各48例,对照组脱落2例。对照组予以常规西药治疗,观察组在对照组基础上给予养心益肾温阳利水法治疗。评价2组临床疗效,比较2组治疗前后中医证候评分、心功能指标、血清N末端脑钠肽前体(NT-proBNP)、肌钙蛋白I(cTnI)、血管紧张素Ⅱ(AngⅡ)水平,观察不良反应发生情况。结果:观察组总有效率为93.75%,高于对照组78.26%(P<0.05)。治疗后,2组主症评分、次症评分和总分较治疗前降低(P<0.05),且观察组主症评分、次症评分和总分低于对照组(P<0.05)。治疗后,2组左室射血分数(LVEF)、心排量(CO)较治疗前升高(P<0.05),左室舒张末期内径(LVEDD)较治疗前降低(P<0.05);且观察组LVEF、CO高于对照组(P<0.05),LVEDD低于对照组(P<0.05)。治疗后,2组血清NT-proBNP、cTnI、AngⅡ水平较治疗前降低(P<0.05),且观察组血清NT-proBNP、cTnI、AngⅡ水平低于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:养心益肾温阳利水法结合常规西药治疗冠心病心力衰竭(心肾阳虚水泛证)可减轻患者临床症状,降低血清NT-proBNP、cTnI、AngⅡ水平,改善心功能。